94 related articles for article (PubMed ID: 15912517)
1. Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence.
Zhao H; Grossman HB; Delclos GL; Hwang LY; Troisi CL; Chamberlain RM; Chenoweth MA; Zhang H; Spitz MR; Wu X
Cancer; 2005 Jul; 104(1):30-5. PubMed ID: 15912517
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
3. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence.
Miyake H; Hara I; Yamanaka K; Gohji K; Arakawa S; Kamidono S
Cancer; 1999 Jul; 86(2):316-24. PubMed ID: 10421268
[TBL] [Abstract][Full Text] [Related]
4. Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis.
Chopra V; Dinh TV; Hannigan EV
Cancer J Sci Am; 1996; 2(5):279-85. PubMed ID: 9166545
[TBL] [Abstract][Full Text] [Related]
5. Angiogenin expression in superficial bladder cancer.
Maeda K; Nomata K; Noguchi M; Kanetake H
Hinyokika Kiyo; 2001 Aug; 47(8):547-52. PubMed ID: 11579593
[TBL] [Abstract][Full Text] [Related]
6. Serum level of angiogenin in breast cancer.
Sheen-Chen SM; Eng HL; Chen WJ; Chou FF; Chen HS
Anticancer Res; 2000; 20(6C):4769-71. PubMed ID: 11205216
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
9. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
10. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Kouba EJ; Lentz A; Wallen EM; Pruthi RS
Urol Oncol; 2009; 27(5):486-90. PubMed ID: 18555706
[TBL] [Abstract][Full Text] [Related]
12. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications.
Musolino C; Alonci A; Bellomo G; Loteta B; Quartarone E; Gangemi D; Massara E; Calabrò L
Eur J Haematol; 2004 Jun; 72(6):416-9. PubMed ID: 15128420
[TBL] [Abstract][Full Text] [Related]
13. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma.
Gohji K; Fujimoto N; Komiyama T; Fujii A; Ohkawa J; Kamidono S; Nakajima M
Cancer; 1996 Dec; 78(11):2379-87. PubMed ID: 8941010
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity.
Hisai H; Kato J; Kobune M; Murakami T; Miyanishi K; Takahashi M; Yoshizaki N; Takimoto R; Terui T; Niitsu Y
Clin Cancer Res; 2003 Oct; 9(13):4852-9. PubMed ID: 14581357
[TBL] [Abstract][Full Text] [Related]
15. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
16. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
[TBL] [Abstract][Full Text] [Related]
17. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients.
Stein JP; Clark P; Miranda G; Cai J; Groshen S; Skinner DG
J Urol; 2005 Apr; 173(4):1163-8. PubMed ID: 15758728
[TBL] [Abstract][Full Text] [Related]
18. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
19. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
20. Plasma glutathione S-transferase pi 1-1 AND alpha 1-1 levels in patients with bladder cancer.
Berendsen CL; Mulder TP; Peters WH
J Urol; 2000 Dec; 164(6):2126-8. PubMed ID: 11061940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
